We developed a novel vaccine approach based on a new class of vaccine immunogens, called variable epitope libraries (VELs). We showed significant tumor growth inhibition and, most importantly, strong suppression of lung metastasis in mice, challenged with the aggressive and highly metastatic 4T1 cell line, after a single immunization using VEL vaccines. We think that the VELs represent a potent new class of cancer immunotherapy and propose the application of the VEL vaccine concept as a true alternative to currently available vaccine platforms.

No abstract

Highlights Antibody-based therapies induce CDR-specific T and B cell responses. Idiotype-anti-idiotype network alters immune system memory compartment. Antigenized antibodies are efficient vaccine immunogen.

No abstract

No abstract